Abstract
MicroRNAs are post-transcriptional regulators of gene expression with tissue-specific expression profiles. Dysregulation of microRNAs has been shown to play a role in carcinogenesis. Although progress has been made in the diagnosis and treatment of many cancers, pancreatic cancer remains an intractable public health problem, causing 6.58% of cancer deaths despite making up less than 3% of cancer diagnoses in the United States. No screening, diagnostic or imaging techniques exist with the sensitivity to detect pancreatic cancer in its early, operable stages. Risk factors include numerous inherited syndromes, diabetes mellitus, and hepatitis C virus infection. Here we review the literature regarding dysregulation of microRNA expression in native pancreas, pancreatic ductal adenocarcinoma (the dominant form of pancreatic cancer), and its risk factors to illuminate the biology and progression of this disease. We explore promising evidence for the use of microRNAs as prognostic and diagnostic tools, and discuss emerging reports on microRNA therapeutics.
Keywords: Biomarker, microRNA, pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, carcinogenesis, malignancy, asymptomatic, papillary, serum, Endocrine.
MicroRNA
Title:No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma
Volume: 1 Issue: 1
Author(s): Philip Y. Cheung, Anna E. Szafranska-Schwarzbach, Annette M. Schlageter, Bernard F. Andruss and Glen J. Weiss
Affiliation:
Keywords: Biomarker, microRNA, pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia, carcinogenesis, malignancy, asymptomatic, papillary, serum, Endocrine.
Abstract: MicroRNAs are post-transcriptional regulators of gene expression with tissue-specific expression profiles. Dysregulation of microRNAs has been shown to play a role in carcinogenesis. Although progress has been made in the diagnosis and treatment of many cancers, pancreatic cancer remains an intractable public health problem, causing 6.58% of cancer deaths despite making up less than 3% of cancer diagnoses in the United States. No screening, diagnostic or imaging techniques exist with the sensitivity to detect pancreatic cancer in its early, operable stages. Risk factors include numerous inherited syndromes, diabetes mellitus, and hepatitis C virus infection. Here we review the literature regarding dysregulation of microRNA expression in native pancreas, pancreatic ductal adenocarcinoma (the dominant form of pancreatic cancer), and its risk factors to illuminate the biology and progression of this disease. We explore promising evidence for the use of microRNAs as prognostic and diagnostic tools, and discuss emerging reports on microRNA therapeutics.
Export Options
About this article
Cite this article as:
Y. Cheung Philip, E. Szafranska-Schwarzbach Anna, M. Schlageter Annette, F. Andruss Bernard and J. Weiss Glen, No miR Quirk: Dysregulation of microRNAs in Pancreatic Ductal Adenocarcinoma, MicroRNA 2012; 1 (1) . https://dx.doi.org/10.2174/2211536611201010049
DOI https://dx.doi.org/10.2174/2211536611201010049 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Negative Influence of Socio-Technical Developments on Eating Habits and Health
Current Nutrition & Food Science Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Promising Potential of Dietary (Poly)Phenolic Compounds in the Prevention and Treatment of Diabetes Mellitus
Current Medicinal Chemistry Purinergic Signalling and Endothelium
Current Vascular Pharmacology The Evolving Roles of Nuclear Cardiology
Current Cardiology Reviews Patent Selections
Recent Patents on Food, Nutrition & Agriculture Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Applications of Peptide Mimetics in Cancer
Current Medicinal Chemistry Neural Pathways and Neuropeptides Mediate the Therapeutic Actions of DPP IV Inhibitors in Type-2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry Proteasome Modulator 9 and Depression in Type 2 Diabetes
Current Medicinal Chemistry Editorial [Hot Topic: Cardiac Cell Therapy: anno 2011 (Executive Guest Editor: Sophie Van Linthout)
Current Pharmaceutical Design Editorial (Mini-Thematic Issue: Current Perspectives in Diabetes and Transplantation)
Current Diabetes Reviews Alport Syndrome: A Comprehensive Review on Genetics, Pathophysiology, Histology, Clinical and Therapeutic Perspectives
Current Medicinal Chemistry Chalcones: As Potent α-amylase Enzyme Inhibitors; Synthesis, <i>In Vitro</i>, and <i>In Silico</i> Studies
Medicinal Chemistry Application in Electrochemistry of Graphene-Modified Electrodes
Micro and Nanosystems The Atherogenic Dyslipidemia of Metabolic Syndrome- Are there New Effective Therapeutic Options Beyond Statins?
Current Drug Therapy On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
Current Drug Metabolism Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology